New proprietary panels in oncology, nephrology, and cardiometabolic care reinforce PMC’s mission to make advanced genomic diagnostics routine in clinical practice
April 1, 2026 — Personalized Medicine Care (PMC) continues to accelerate the adoption of precision medicine with the American Medical Association (AMA) granting Proprietary Laboratory Analyses (PLA) code approval for four newly developed diagnostic tests. This milestone builds on PMC’s growing portfolio of clinically actionable genomic tools designed to improve diagnostic accuracy, guide treatment decisions, and expand access to personalized care.
The newly approved tests span oncology, nephrology, and cardiometabolic disease—three areas where unmet clinical need and complexity demand more advanced diagnostic solutions.
Advancing Cancer Detection with Enhanced Genomic Insight
Among the approvals is OncoDx® – Hereditary Germline Cancer Genetics Panel, a next-generation test designed to improve detection of hereditary cancer risks. The panel integrates short-read sequencing with digital MLPA (dMLPA) technology, enabling more comprehensive identification of copy number variations.
By incorporating dMLPA, the test increases diagnostic yield by 8.5–10% in cancer populations, offering clinicians a more complete genetic picture and supporting earlier, more informed intervention strategies.
Introducing Novel Pharmacogenetic Panels for Kidney and Cardiometabolic Care
PMC also received PLA approval for two first-of-their-kind pharmacogenetic panels:
- RenaPGx® – Renal Pharmacogenetic Test: The only nephrology-specific pharmacogenetic panel currently available, designed to guide medication selection, dosing optimization, and identify genetic modifiers impacting kidney disease progression and transplant outcomes.
- CKM PGx® – Cardiovascular-Kidney-Metabolic Pharmacogenetic Panel: A first-in-class panel integrating drug-gene insights across cardiovascular, renal, and metabolic pathways—helping clinicians tailor therapies for patients managing complex, high-burden chronic conditions.
Together, these tests reflect a growing shift toward multi-system, genomics-driven care models, where treatment decisions are informed by a patient’s unique genetic profile across interconnected disease states.
Expanding Access to Comprehensive Renal Genetic Testing
Rounding out the approvals is RenaXome® – Renal Disease Whole Exome Sequencing, a comprehensive genome-wide sequencing panel designed for both pediatric and adult populations.
Built to address the challenges of diagnosing rare and complex inherited kidney disorders, RenaXome® provides clinicians with a powerful tool to uncover underlying genetic causes—many of which may otherwise go undetected using standard diagnostic approaches. Its clinical utility is supported by research published in the New England Journal of Medicine (2019;380:142-151), underscoring the growing importance of genomic sequencing in nephrology.
Building Momentum in Precision Medicine
This latest set of approvals reinforces PMC’s ongoing strategy to expand its proprietary test menu with clinically differentiated, high-impact diagnostics. It also builds on the company’s previous AMA PLA milestone for its renal-focused panel, signaling continued momentum in advancing precision medicine across multiple therapeutic areas.
By combining innovative technologies, disease-specific expertise, and a commitment to clinical utility, PMC is positioning itself at the forefront of making precision medicine not just possible—but practical and scalable in everyday care.
CPT Proprietary Laboratory Analyses Codes Long Descriptors | AMA
